Cerebral Amyloid Angiopathy
Conditions
Brief summary
A pre-post study will be conducted to assess whether treatment with LXB, nVNS or a combination of both interventions can enhance the clearance of Aβ in patients with CAA. A total of 60 subjects, 30 with sCAA and 30 with D-CAA, will be randomly assigned to receive LXB, or both interventions. The primary outcome measure will be the morning levels of Aβ40 and Aβ42 in cerebrospinal fluid (CSF) before and after the intervention. The investigators will assess disease progression with (non-)haemorrhagic imaging markers on 7-Tesla Magnetic Resonance Imaging (7-T MRI) as a secondary outcome. Additionally, the activity of the glymphatic system by means of fluid dynamics will be assessed using 7-T MRI.
Interventions
DRUGXYWAV
Daily before bedtime for 3 months
DEVICEgammaCore Sapphire
Twice daily for 3 months
Sponsors
Leiden University Medical Center
The Dutch Brain Foundation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
pre-post study with additional randomisation
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with D-CAA with a proven amyloid precursor protein (APP) mutation or a history of ≥1 lobar intracerebral haemorrhage (ICH) and a positive family history for D-CAA in ≥1 first degree relative * Age ≥30 years old * ≤ 2 symptomatic ICH (occurrence of ICH at least \> 1 year ago) or presence of ≥ 1 haemorrhagic marker (cortical superficial siderosis, cerebral microbleeds) or non-haemorrhagic marker (white matter hyperintensities, enlarged perivascular spaces). * When presymptomatic, patients are aware that they have D-CAA * Probable sporadic CAA (sCAA) according to the Modified Boston criteria 2.0 * Age ≥50 years old * ≤ 2 symptomatic ICH (occurrence of ICH at least \> 1 year ago) * Provisional CAA when the criteria for probable sCAA are not met due to presence of deep haemorrhagic lesions but there are mostly lobar microbleeds (MBs) and cortical superficial siderosis (cSS) present or a ratio of 10 times more lobar MBs than deep MBs without cSS. * Age ≥50 years old * ≤ 2 symptomatic ICH (occurrence of ICH at least \> 1 year ago) * Participants able to read and understand the patient information folder and who freely provide written informed consent
Exclusion criteria
* Modified Rankin Score ≥ 4 * A life expectancy of less than six months * Pregnancy/breast feeding * Contraindications for lumbar puncture * Unwillingness to refrain from consuming \> 1 alcohol unit per day and not later than 8 pm, during the intervention period. Contraindications for using LXB: * Sleep apnea; patients will be screened with respiratory polygraphy before inclusion and screening by questionnaire during intervention with LXB. * Restless legs (RLS) needing active treatment with RLS medication. * Currently suffering from severe depression and using medication or receiving cognitive therapy. * Porphyria * Succinic semialdehyde dehydrogenase (SSADH-)deficiency * Use of opiates, barbiturates, sedatives (dexmedetomidine, temazepam, oxazepam, midazolam) * Use certain medication before inclusion: * When benzodiazepine is used: a two nights washout before the intervention (T3) will be started, is needed. * When LXB or SXB is used before inclusion: one week washout before inclusion and no use of LXB or SXB during inclusion except for the intervention dose. Contraindications for lumbar puncture: * Compression of the spinal cord * Signs and symptoms of increased intracranial pressure * Local infections of the skin at the puncture site * Coagulopathy or thrombocytopenia (\<100) * (Use of acetylsalicylic acid, NSAIDs, COX2 inhibitors or prophylactic low-molecular-weight heparin are no contraindications for lumbar puncture.) * Participants deemed at risk for brain replacement due to known aqueduct stenosis, Arnold chiari malformations. * Participants with a lumbo-sacral neural tube defect or who have a ventriculo-atrial or ventriculo-peritoneal drain. Contraindications for nVNS: * An active implantable medical device such as a pacemaker, deep brain stimulator, or any implanted electronic device. * A recent (\< 1 month) brain infarction or transient ischemic attack due to a symptomatic stenosis or dissection of the carotid artery (in these patients the other side will be stimulated unless a significant stenosis or dissection on the other side is present as well). * If someone knows to have a structural abnormality e.g. lymphadenopathy, previous surgery or abnormal anatomy (in these patients the other side will be stimulated) * Metal cervical spine hardware or metallic implant near the stimulation site * Cervical vagotomy (in these patients the other side will be stimulated) Contraindications for 7 Tesla MRI as determined by the 7 Tesla safety committee. Examples of possible contra-indications are: * Claustrophobia * Pacemakers and defibrillators * Nerve stimulators * Intracranial clips * Intraorbital or intraocular metallic fragments * Cochlear implants * Ferromagnetic implants * Hydrocephalus pump * Intra-uterine device * Permanent make-up * Tattoos above the shoulders Specific contraindications for checkerboard functional Magnetic Resonance Imaging (fMRI): * Seizure within prior year * Photosensitive epilepsy * Non-correctable visual impairment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Morning amyloid-beta 40 and 42 levels in cerebrospinal fluid | 3 months | Difference between before and after intervention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease progression with (non-)haemorrhagic imaging markers on 7-T MRI | 2x 3 months | Macrobleeds |
| Activity of the glymphatic system by means of fluid dynamics on 7-T MRI | 2x 3 months | CSF-mobility (in mm2/s) |
| Other liquid biomarkers | 3 months | Difference in Aβ-levels 40 and 42 in CSF comparing the three intervention groups and the BATMAN placebo control group. |
| Questionnaires | 2x 3 months | Cognitive status using the Montreal Cognitive Assessment (MoCA) |
| Intervention monitoring | 3 months | Compliance, side effects and tolerability of nVNS and LXB |
Countries
Netherlands
Outcome results
None listed